Should I buy or sell Invitae stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong sell" NVTA shares. View NVTA analyst ratings or view top-rated stocks .

What is Invitae's stock price target for 2024?

3 brokers have issued twelve-month price targets for Invitae's shares. Their NVTA share price targets range from $0.50 to $1.50. On average, they predict the company's share price to reach $1.00 in the next year. This suggests a possible upside of 36,937.0% from the stock's current price. View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts .

How have NVTA shares performed in 2024?

Invitae's stock was trading at $0.6268 on January 1st, 2024. Since then, NVTA shares have decreased by 99.6% and is now trading at $0.0027. View the best growth stocks for 2024 here .

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) announced its quarterly earnings data on Tuesday, May, 9th. The medical research company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.04. The medical research company earned $117.36 million during the quarter, compared to the consensus estimate of $116.57 million. Invitae had a negative trailing twelve-month return on equity of 6,100.71% and a negative net margin of 299.14%. The company's revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.78) EPS.

What ETFs hold Invitae's stock?

ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and Global X Telemedicine & Digital Health ETF (EDOC) . Global X Genomics & Biotechnology ETF (GNOM) .

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com . Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA) , Block (SQ) , Roku (ROKU) , Tesla (TSLA) , Alibaba Group (BABA) , Trade Desk (TTD) , Shopify (SHOP) , Salesforce (CRM) , Advanced Micro Devices (AMD) and Okta (OKTA) .

When did Invitae IPO?

Invitae (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:NVTA

Invitae (NVTA) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free NVTA Stock Alerts

$0.0034

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.0001
▼
$0.0089
50-Day Range: $0.00
▼
$0.09
52-Week Range: $0.02
▼
$0.02

Volume: 680,460 shs
Average Volume: 23.72 million shs
Market Capitalization: $907,834.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.00

Get Invitae alerts:

Invitae MarketRank™ Stock Analysis

Analyst Rating: Strong Sell
1.00 Rating Score
Upside/Downside: 36,937.0% Upside
$1.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -1.13
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.05) to ($0.89) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

2.5

Analyst's Opinion

Consensus Rating
Invitae has received a consensus rating of Strong Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 3 sell ratings.
Amount of Analyst Coverage
Invitae has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for NVTA.

0.0

Dividend Strength

Dividend Yield
Invitae does not currently pay a dividend.
Dividend Growth
Invitae does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Invitae has received a 71.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private genetic testing services" and "Diagnostic test kits" products. See details.
Environmental Sustainability
The Environmental Impact score for Invitae is -1.13.

1.4

News and Social Media Coverage

News Sentiment
Invitae has a news sentiment score of -0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Invitae this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for NVTA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Invitae to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Invitae insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.74% of the stock of Invitae is held by insiders.
Percentage Held by Institutions
61.28% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Invitae are expected to grow in the coming year, from ($1.05) to ($0.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Invitae has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About Invitae Stock (NYSE:NVTA)

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

NVTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NVTA Stock News Headlines

April 15, 2024 | americanbankingnews.com

Invitae (NYSE:NVTA) Receives New Coverage from Analysts at StockNews.com

April 11, 2024 | finance.yahoo.com

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

April 11, 2024 | prnewswire.com

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

April 2, 2024 | bizjournals.com

Pioneering cancer test company wants court to slow potential sale of Invitae's cancer-monitoring products

March 12, 2024 | finance.yahoo.com

Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification

March 11, 2024 | reuters.com

NVTA.PK

March 9, 2024 | reuters.com

NVTA.N

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

March 6, 2024 | finanznachrichten.de

Invitae Corporation: Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results

March 6, 2024 | prnewswire.com

Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results

March 5, 2024 | prnewswire.com

Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting

March 3, 2024 | finance.yahoo.com

NVTA Jun 2024 0.500 put

February 26, 2024 | finance.yahoo.com

NVTA Jan 2026 1.500 call

February 17, 2024 | finance.yahoo.com

NVTA Mar 2024 0.500 put

February 15, 2024 | msn.com

Invitae gets court approval for five-month bankruptcy sale

February 15, 2024 | bizjournals.com

Genetic testing pioneer Invitae files for bankruptcy protection

February 14, 2024 | msn.com

Genetic Test Provider Invitae (OTC:NVTA) Files for Bankruptcy

February 14, 2024 | msn.com

Genetic test maker Invitae files for bankruptcy protection in US

February 14, 2024 | finance.yahoo.com

Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process

February 13, 2024 | reuters.com

Genetic test maker Invitae files for bankruptcy protection in US

February 13, 2024 | prnewswire.com

Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process

February 9, 2024 | edition.cnn.com

Invitae Corp.

February 6, 2024 | investorplace.com

NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy

February 6, 2024 | finance.yahoo.com

NYSE to Commence Delisting Proceedings Against Invitae Corporation (NVTA)

February 6, 2024 | finanznachrichten.de

Invitae Corporation: Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

February 5, 2024 | investorplace.com

Why Is Invitae (NVTA) Stock Down 75% Today?

See More Headlines

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/09/2023
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NYSE:NVTA
CUSIP: N/A
CIK: 1501134
Web: www.invitae.com
Phone: (628) 213-3369
Fax: N/A
Employees: 1,700
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.00
High Stock Price Target: $1.50
Low Stock Price Target: $0.50
Potential Upside/Downside: +49,900.0%
Consensus Rating: Strong Sell
Rating Score (0-4): 1.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-3,106,290,000.00
Net Margins: -299.14%
Pretax Margin: -301.93%
Return on Equity: -6,100.71%
Return on Assets: -19.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.39
Quick Ratio: 2.25

Sales & Book Value

Annual Sales: $481.58 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.42 per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 267,010,000
Free Float: 284,373,000
Market Cap: $534,020.00
Optionable: Optionable
Beta: 1.59

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Randal W. Scott Ph.D. (Age 66)
Co-Founder & Chairman of the Board
Comp: $50k
Mr. Kenneth D. Knight (Age 63)
President, CEO & Director
Comp: $1.4M
Mr. Thomas R. Brida (Age 53)
General Counsel, Chief Compliance Officer & Secretary
Comp: $776.72k
Ms. Ana J. Schrank (Age 58)
Chief Accounting Officer & CFO
Dr. David B. Sholehvar M.D. (Age 56)
Chief Operating Officer
Ms. Hoki Luk (Age 48)
Head of Investor Relations and Capital Markets
Ms. Shelly D. Guyer (Age 64)
Chief Sustainability Officer
Comp: $430.44k
Ms. Desarie French
Chief Talent Officer
Dr. W. Michael Korn M.D.
Chief Medical Officer
Mr. Robert Guigley
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Invitae stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong sell" NVTA shares.
View NVTA analyst ratings or view top-rated stocks.
What is Invitae's stock price target for 2024?: 3 brokers have issued twelve-month price targets for Invitae's shares. Their NVTA share price targets range from $0.50 to $1.50. On average, they predict the company's share price to reach $1.00 in the next year. This suggests a possible upside of 36,937.0% from the stock's current price.
View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts.
How have NVTA shares performed in 2024?: Invitae's stock was trading at $0.6268 on January 1st, 2024. Since then, NVTA shares have decreased by 99.6% and is now trading at $0.0027.
View the best growth stocks for 2024 here.
How were Invitae's earnings last quarter?: Invitae Co. (NYSE:NVTA) announced its quarterly earnings data on Tuesday, May, 9th. The medical research company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.04. The medical research company earned $117.36 million during the quarter, compared to the consensus estimate of $116.57 million. Invitae had a negative trailing twelve-month return on equity of 6,100.71% and a negative net margin of 299.14%. The company's revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.78) EPS.
What ETFs hold Invitae's stock?: ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and Global X Telemedicine & Digital Health ETF (EDOC).Global X Genomics & Biotechnology ETF (GNOM).

What is Sean George's approval rating as Invitae's CEO?: 59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.
What other stocks do shareholders of Invitae own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).
When did Invitae IPO?: Invitae (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
How do I buy shares of Invitae?: Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVTA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Invitae (NVTA) Stock Price, News & Analysis

Invitae MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Invitae Stock (NYSE:NVTA)

NVTA Stock Price History

NVTA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NVTA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™